bioMérieux launches eMAG®, a new generation automated system for the extraction of DNA and RNA
10 Novembre 2016 - 7:00AM
Business Wire
Regulatory News:
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20161109006375/en/
eMAG (c)bioMerieux
bioMérieux (Paris:BIM), a world leader in the field
of in vitro diagnostics, has announced the launch of
eMAG®, its new molecular biology platform for the extraction of
nucleic acids (DNA, RNA).
eMAG® builds on the quality, robustness and ease of use that
have made the NucliSENS® easyMAG® platform so successful. The new
eMAG® features automation from the primary sample tube, greater
traceability and higher throughput, in addition to an unparalleled
degree of flexibility, not previously available on an automated
system for the extraction of nucleic acids.
Extraction is the first step of molecular biology testing,
making it possible to obtain purified nucleic acids that will
subsequently be amplified and detected. The efficiency of the
extraction of nucleic acids from a sample therefore has a decisive
impact on the quality of a diagnostic test’s final result. Because
there may be various sample types, this step is particularly
complex.
eMAG® uses BOOM® technology, the gold standard in the field of
molecular diagnostics, for the extraction of DNA and RNA.
The new eMAG® system may be used with a broad variety of
biological samples: whole blood, plasma, serum, stool, respiratory
samples and cerebrospinal fluid. With the new eMAG® system, it is
possible to obtain excellent quality purified nucleic acids using a
standardized extraction protocol.
eMAG® can extract 48 samples in 90 minutes directly from a
primary sample, and handles all sample types in a single series.
The enhanced flexibility and traceability of this automated, high
throughput platform allow laboratories to monitor patients as soon
as this becomes necessary, regardless of the sample type.
“As pioneers of diagnostics for over 50 years, we are proud to
provide our customers with high medical value automated solutions
that meet their needs for improved laboratory workflow,
optimization, traceability and efficiency,” said Randy Rasmussen,
CEO of BioFire Diagnostics and VP Molecular Biology at
bioMérieux. “The remarkable flexibility of eMAG®, its high
throughput, and the extraction performance illustrate our
commitment to high quality molecular solutions for the diagnosis of
infectious diseases.”
eMAG® is CE-marked and available on the European and United
States markets. A program to gradually launch the system in other
countries will be rolled out in early 2017.
About bioMérieux
Pioneering Diagnostics
A world leader in the field of in vitro diagnostics for 50
years, bioMérieux is present in more than 150 countries
through 42 subsidiaries and a large network of distributors. In
2015, bioMérieux’s revenues reached €1,965 million with 90% of
international sales.
bioMérieux provides diagnostic solutions (reagents, instruments,
software) which determine the source of disease and contamination
to improve patient health and ensure consumer safety. Its products
are mainly used for diagnosing infectious diseases. They are also
used for detecting microorganisms in agri-food, pharmaceutical and
cosmetic products.
(Symbol: BIM/Reuters: BIOX.PA/Bloomberg: BIM.FP – ISIN:
FR0010096479).Corporate website: www.biomerieux.comInvestor website: www.biomerieux-finance.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161109006375/en/
Investor RelationsbioMérieuxSylvain Morgeau, + 33
4 78 87 22 37investor.relations@biomerieux.comorMedia
RelationsbioMérieuxAurore Sergeant, + 33 4 78 87 54
75media@biomerieux.comorImage SeptLaurence Heilbronn, + 33 1
53 70 74 64lheilbronn@image7.frorClaire Doligez, + 33 1 53 70 74
48cdoligez@image7.fr
Biomerieux (EU:BIM)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Biomerieux (EU:BIM)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024
